Company intelligence / Profile preview

Nan Fung Technology

Hong Kong

Ownership: Private
Development stage: Other

Overview

Nan Fung Group is a privately held Hong Kong-based conglomerate primarily focused on property development, with a significant and active investment arm in life sciences through its subsidiary Nan Fung Life Sciences and its venture capital firm, Pivotal bioVenture Partners. Its life science investments target drug development companies from preclinical to Phase 1, focusing on traditional modalities like biologics, antibodies, and small molecules.

Modalities: BiologicsAntibodiesSmall molecules
Industry: Investors

Partnerships

Pivotal bioVenture Partners (funded with $300 million for Fund I in 2017, $389 million for Fund II)Aligos Therapeutics (via Pivotal)Karuna Therapeutics (via Pivotal)Akouos Inc (via Pivotal)Bolt Biotherapeutics (via Pivotal)Evommune (via Pivotal)Avalyn Pharma (via Pivotal)

Beyond the preview

Go deeper on Nan Fung Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nan Fung Technology.

Explore the full profile